TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
enGene Holdings ( (ENGN) ) has provided an announcement.
enGene Holdings Inc. announced that Alex Nichols, Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference. This presentation highlights enGene’s ongoing efforts in advancing their lead program, detalimogene voraplasmid, for treating Non-Muscle Invasive Bladder Cancer, potentially impacting their market positioning and offering new hope for patients with high clinical needs.
The most recent analyst rating on (ENGN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on enGene Holdings stock, see the ENGN Stock Forecast page.
Spark’s Take on ENGN Stock
According to Spark, TipRanks’ AI Analyst, ENGN is a Neutral.
enGene Holdings shows significant financial challenges, with no revenue generation and persistent losses impacting both income and cash flow statements. Technical indicators suggest bearish momentum, with the stock underperforming key moving averages. The valuation is further hampered by a negative P/E ratio and absence of dividends. These factors collectively result in a low overall stock score, highlighting the company’s urgent need to establish a revenue model and improve operational efficiency.
To see Spark’s full report on ENGN stock, click here.
More about enGene Holdings
enGene Holdings Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for delivery to mucosal tissues and other organs. Their primary product, detalimogene voraplasmid, targets Non-Muscle Invasive Bladder Cancer and is currently in a Phase 2 trial.
Average Trading Volume: 1,246,087
Technical Sentiment Signal: Buy
Current Market Cap: $478.5M
Find detailed analytics on ENGN stock on TipRanks’ Stock Analysis page.